DAPT Duration - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Abstract

'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry
Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial

Original Research

2021 Jul 2;zuab033.

JOURNAL：Eur Heart J Acute Cardiovasc Care.

'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial

AS Gamal, H Hara, PW Serruys et al.

2352

Keywords: DAPT; GLOBAL LEADERS; PCI; Ticagrelor; STEMI

Full Text PDF